RMTI vs. BOLT, AADI, OCUP, XLO, NBRV, NXTC, NRXP, CALC, CLNN, and ELDN
Should you be buying Rockwell Medical stock or one of its competitors? The main competitors of Rockwell Medical include Bolt Biotherapeutics (BOLT), Aadi Bioscience (AADI), Ocuphire Pharma (OCUP), Xilio Therapeutics (XLO), Nabriva Therapeutics (NBRV), NextCure (NXTC), NRx Pharmaceuticals (NRXP), CalciMedica (CALC), Clene (CLNN), and Eledon Pharmaceuticals (ELDN). These companies are all part of the "pharmaceutical preparations" industry.
Bolt Biotherapeutics (NASDAQ:BOLT) and Rockwell Medical (NASDAQ:RMTI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations, valuation and community ranking.
In the previous week, Bolt Biotherapeutics had 1 more articles in the media than Rockwell Medical. MarketBeat recorded 2 mentions for Bolt Biotherapeutics and 1 mentions for Rockwell Medical. Bolt Biotherapeutics' average media sentiment score of 0.00 beat Rockwell Medical's score of -0.16 indicating that Rockwell Medical is being referred to more favorably in the news media.
Rockwell Medical received 221 more outperform votes than Bolt Biotherapeutics when rated by MarketBeat users. However, 68.38% of users gave Bolt Biotherapeutics an outperform vote while only 57.33% of users gave Rockwell Medical an outperform vote.
Bolt Biotherapeutics has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, Rockwell Medical has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500.
Bolt Biotherapeutics presently has a consensus target price of $7.00, indicating a potential upside of 494.28%. Rockwell Medical has a consensus target price of $7.00, indicating a potential upside of 376.19%. Given Rockwell Medical's higher possible upside, equities research analysts plainly believe Bolt Biotherapeutics is more favorable than Rockwell Medical.
86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 23.3% of Rockwell Medical shares are held by institutional investors. 28.4% of Bolt Biotherapeutics shares are held by company insiders. Comparatively, 2.2% of Rockwell Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Rockwell Medical has higher revenue and earnings than Bolt Biotherapeutics. Rockwell Medical is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Rockwell Medical has a net margin of -10.09% compared to Rockwell Medical's net margin of -878.58%. Bolt Biotherapeutics' return on equity of -39.17% beat Rockwell Medical's return on equity.
Summary
Rockwell Medical beats Bolt Biotherapeutics on 9 of the 16 factors compared between the two stocks.
Get Rockwell Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for RMTI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RMTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rockwell Medical Competitors List
Related Companies and Tools
